![\"\"](\"https:\/\/www.stocktitan.net\/img\/icons\/Google_News_icon.svg\"){kind=icon}
<\/p>\n
\n
\n
\n
\n
<\/p>\n
Key Terms<\/p>\n
\n
\n small molecule
\n
\n medical
\n
\n
<\/p>\n
A small molecule is a low-weight chemical compound that can enter cells easily and interact with specific proteins or biological pathways to change how they work, much like a small key fitting into a lock. Investors care because small molecules are a common and often faster route to develop medicines, can be manufactured at scale, and may offer clearer regulatory and commercial paths compared with larger biologic therapies, affecting potential costs, timelines and returns.<\/p>\n
<\/p>\n
\n
\n ai-driven drug discovery
\n
\n technical
\n
\n
<\/p>\n
AI-driven drug discovery uses advanced computer programs to spot promising drug targets and molecules by analyzing large sets of biological and chemical data, accelerating steps that used to take many years of lab work. Investors care because it can cut research costs, shorten development timelines and raise the odds of finding viable medicines\u2014think of it as using a smart metal detector to find valuable items more efficiently than digging at random\u2014while still carrying scientific and regulatory risk.<\/p>\n
<\/p>\n
\n
\n clinical trials
\n
\n medical
\n
\n
<\/p>\n
Clinical trials are carefully controlled studies that test whether a new drug, device or treatment is safe and effective in people, moving through successive stages that increase the number of participants and the rigor of testing. Investors care because trial outcomes determine whether a product can be approved and sold, shaping a company\u2019s future revenue, valuation and risk profile\u2014think of it as proof-of-concept testing that decides if a prototype becomes a market-ready product.<\/p>\n
<\/p>\n
\n
\n
\n
\n
\n
\n
\n
<\/p>\n
<\/p>\n
See more from StockTitan in Google Search and AI answers.
\n Adds StockTitan as a preferred source \u00b7 opens Google\n <\/p>\n
\n
\n
\n
\n
\n
\n 06\/22\/2026 – 08:00 AM
\n
\n
<\/p>\n
Collaboration focuses on small molecule discovery<\/p>\n
Bayer to leverage Iambic\u2019s AI platform to address hard-to-drug targets<\/p>\n
Collaboration will strengthen Bayer\u2019s research and development portfolio by harnessing AI to accelerate drug discovery<\/p>\n
BERLIN & SAN DIEGO–(BUSINESS WIRE)–
\nBayer and Iambic Therapeutics Inc., a clinical-stage life science and technology company developing novel medicines using its AI-driven platform, today announced a drug discovery collaboration in which Bayer will discover new medicines using Iambic\u2019s AI-driven platform. The collaboration is focused on small molecule discovery.<\/p>\n
\nThe collaboration will leverage Iambic\u2019s AI-driven drug discovery platform, including its flagship AI technologies, Enchant & NeuralPLexer, to identify novel drug entry points and differentiated molecules to address otherwise hard-to-drug targets that will enhance Bayer\u2019s early portfolio.<\/p>\n
\n\u201cThis collaboration exemplifies our shared ambition to harness AI as a strategic driver of innovation in drug discovery and our focus on building high-impact collaborations that translate cutting-edge technology into patient value.\u201d said Juergen Eckhardt, M.D., Head of Business Development and Licensing at Bayer Pharmaceuticals. \u201cBy collaborating with Iambic, we bring together complementary capabilities to accelerate scientific insights and improve decision-making across the R&D value chain.\u201d<\/p>\n
\nTraditional drug discovery takes 10-15 years and costs around USD 2.6 billion, yet more than 90 percent of candidates fail in clinical trials.1,2,3 By using AI-based molecular optimization, the collaboration aims to identify differentiated hit molecules, accelerate optimization timelines, and strengthen Bayer’s pipeline ahead of the next decade.<\/p>\n
\n\u201cIambic is proving that better technology leads to better medicines, both in our own hands and with visionary partners like Bayer,\u201d said Tom Miller, PhD, Co-Founder and CEO, Iambic. \u201cThrough this collaboration, Bayer secures access to industry-leading technology, including Iambic\u2019s frontier AI models Enchant and NeuralPLexer, and together we expand the universe of potential life-saving medicines.\u201d<\/p>\n
\nUnder terms of the agreement, Iambic will receive an upfront payment as well as milestone and royalty payments.<\/p>\n
\nAbout Iambic<\/p>\n
\nIambic is proving that better technology leads to better medicines. By pioneering molecular superintelligence \u2014 integrating proprietary AI with automated, high-throughput experimentation \u2014 we are transforming how medicines are made. Our platform was validated by the discovery of a novel drug candidate advanced to clinic in about one-third industry-standard time, along with a diverse preclinical pipeline. Our leading AI technologies include Enchant and NeuralPLexer for multimodal endpoint prediction designed to improve the speed, precision, and success rates of drug discovery and clinical development. At Iambic, we are building the engine that will power the future of medicine. | iambic.ai<\/a><\/p>\n \nAbout Bayer<\/p>\n \nBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, \u201cHealth for all, Hunger for none,\u201d the company\u2019s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com<\/a>.<\/p>\n \nFind more information at https:\/\/pharma.bayer.com\/ \nForward-Looking Statements<\/p>\n \nThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer\u2019s public reports which are available on the Bayer website at www.bayer.com<\/a>. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.<\/p>\n \nBayer AG is a holding company with operating subsidiaries worldwide. References to \u201cBayer\u201d or \u201cthe company\u201d herein may refer to one or more subsidiaries as context requires.<\/p>\n \n\u00a0<\/p>\n View source version on businesswire.com: https:\/\/www.businesswire.com\/news\/home\/20260621558588\/en\/<\/a><\/p>\n \nBayer Global Media: \nBayer U.S. Media:
\n<\/a>
Follow us on Facebook: http:\/\/www.facebook.com\/bayer<\/a><\/p>\n<\/p>\n
\n
Lisa Varrelmann, phone: +49 1746466492
\n
Email: lisa.varrelmann@bayer.com<\/a><\/p>\n
\n
Elaine Col\u00f3n
\n
Email: elaine.colon@bayer.com<\/a><\/p>\n